Chronic Kidney Disease
Conditions
Brief summary
The Chronic Kidney Disease Engagement System is currently in place for 1700 adults receiving care from Empire Physicians Medical Group (EPMG), an Independent Practice Association located in Palm Desert, California. The system monitors routine clinical laboratory test results and send messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. This study will assess what happens to laboratory results, utilization of laboratory tests, and costs of care when ther system is discontinued.
Detailed description
The Chronic Kidney Disease Engagement System is currently in place for 1700 adults receiving care from Empire Physicians Medical Group (EPMG), an Independent Practice Association located in Palm Desert, California. The system monitors routine clinical laboratory test results and send messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care. It has been used for over three years and appears to have improved adherence to Chronic Kidney Disease (CKD) treatment guidelines by influencing both patient and provider actions. EPMG wishes to restrict the service to those patients with advanced CKD and discontinue it for CKD stages 1-3. The investigators propose implementing this new policy in a randomized fashion with one half of the current early stage patients continuing to receive the service while the other half will no longer receive messages. The investigators will monitor laboratory results and health care utilization for both groups to determine what effect, if any, discontinuation has on quality of care. Human subjects will either continue to receive letters from the service when their tests are overdue or require additional clinical attention, or will no longer receive the service. All subjects will continue to receive care from their providers. The main outcomes include the frequency of recommended tests for CKD, the level of those tests, and utilization of health care services as indicated by claims data provided by EPMG. No additional data collection will occur beyond that which has been routinely done for clinical care. The study will continue for 36 months.
Interventions
OTHERPatient Engagement
The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
Sponsors
Patient Engagement Systems
Empire Physicians Medical Group
University of Vermont
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Receiving services from Patient Engagement Services at randomization. CKD Stages 1, 2 or 3. Under the care of Empire Physicians Medical Group of Palm Desert, California.
Exclusion criteria
Patient refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Claims paid in past 12 months for covered services | 3 years | Total and breakdown by categories |
Secondary
| Measure | Time frame |
|---|---|
| Estimated glomerular filtration | 3 years |
| Hemoglobin test completed within time allotted per disease stage | 3 years |
| Serum calcium test completed within time allotted per disease stage | 3 years |
| Serum phosphorus test completed within time allotted per disease stage | 3 years |
| Lipid test completed within time allotted per disease stage | 3 years |
| Serum parathyroid hormone test completed within time allotted per disease stage | 3 years |
| Serum albumin test completed within time allotted per disease stage | 3 years |
| Serum electrolytes test completed within time allotted per disease stage | 3 years |
| Latest LDL <100 mg/dl AND completed within time allotted per disease stage | 3 years |
| Urine albumin-to-creatinine ratio test completed within time allotted per disease stage | 3 years |
Countries
United States
Outcome results
None listed